AI Article Synopsis
- The androgen receptor (AR) has been a key focus in treating prostate cancer for over 50 years, but new research shows it's also found in other cell types within the tumor microenvironment.
- Current AR-targeted therapies can cause side effects like bone issues and increased risk for heart-related diseases, hinting at AR's broader impact.
- Recent advancements in technology have revealed important roles for AR outside cancer cells, affecting how prostate cancer progresses and how patients respond to treatment.
Article Abstract
Given the central role of the androgen receptor (AR) in prostate cancer cell biology, AR-targeted therapies have been the backbone of prostate cancer treatment for over 50 years. New data indicate that AR is expressed in additional cell types within the tumor microenvironment. Moreover, targeting AR for the treatment of prostate cancer has established side effects such as bone complications and an increased risk of developing cardiometabolic disease, indicating broader roles for AR. With the advent of novel technologies, such as single-cell approaches and advances in preclinical modeling, AR has been identified to have clinically significant functions in other cell types. In this mini-review, we describe new cancer cell-extrinsic roles for AR within the tumor microenvironment as well as systemic effects that collectively impact prostate cancer progression and patient outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413433 | PMC |
| http://dx.doi.org/10.1210/endocr/bqad078 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lesson for the clinical nephrologist: thrombotic microangiopathy associated with metastatic prostate cancer.
J Nephrol
December 2024
Division of Nephrology, Cantonal Hospital Aarau, Aarau, Switzerland.
MUC1 expression is associated with ST3GAL2 and negatively correlated with the androgen receptor in castration-resistant prostate cancer.
Glycoconj J
December 2024
Department of Urology, University of the Ryukyus Graduate School of Medicine, 207 Uehara, Nishihara, Nakagami-gun, Okinawa, 903-0215, Japan.
Stage-specific embryonic antigen-4 (SSEA-4) is a developmentally regulated antigen, while expression level of SSEA-4 and / or its synthase ST3GAL2 is associated with prognosis in various malignancies. We have reported a prominent increase of SSEA-4 in castration-resistant prostate cancer (CRPC) and its negative correlation with the androgen receptor (AR). Meanwhile, loss of AR has increased to approximately 30% with the growing use of androgen receptor signaling inhibitor for metastatic CRPC (mCRPC).
View Article and Find Full Text PDFCombined Ribociclib and NU7026 administration enhances radio-sensitivity by inhibiting DNA repair in prostate cancer.
Naunyn Schmiedebergs Arch Pharmacol
December 2024
Department of Urology, Tangdu Hospital, Fourth Military Medical University, No.569 Xinsi Road, Xi'an, 710038, Shaanxi, China.
Radiosensitivity is critical for clinical outcomes and overall survival of prostate cancer patients treated with irradiation. Ribociclib and NU7026 have been reported as radiosensitizers in cancer cells, but which are inadequately understood in prostate cancer cells. The present study was performed to investigate the effects of ribociclib, NU7026, and their combination on the radiosensitivity of prostate cancer cells.
View Article and Find Full Text PDFEffects of postoperative physical exercise rehabilitation on cardiorespiratory fitness, functional capacity and quality of life in patients with colorectal, breast, and prostate cancer - a systematic review and meta-analysis.
J Cancer Res Clin Oncol
December 2024
Institute of Sports Medicine & Prevention, University Leipzig, Leipzig, Germany.
Purpose: The reduced cardiorespiratory fitness (CRF) and functional capacity following surgical procedures and during cancer treatments is a major risk factor for morbidity and mortality among patients with cancer. We aimed to assess the impact of endurance and combined resistance exercise interventions during the postoperative rehabilitation period for patients with colorectal, breast, and prostate cancer.
Methods: A systematic search was conducted in MEDLINE Pubmed, Web of Science, and Cochrane Library until October 2023 for randomized controlled trials that assessed exercise interventions (aerobic/endurance; resistance or combined training) on postoperative patients with cancer.
MRI-directed Micro-US-guided Transperineal Focal Laser Ablation for Localized Prostate Cancer: A 1-year Follow-up Study.
Radiology
December 2024
From the Departments of Radiology (F.C., A.L.) and Urology (M.G.), Clinique de l'Alma, 166 Rue de l'Université, 75007 Paris, France; Department of Urology, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands (K.d.B., L.v.R.); and Department of Pathology, i-Path Institut de Pathologie des Hauts-de-France, Amiens, France (P.C.).
Background MRI-guided focal laser ablation (FLA) is a promising treatment in localized prostate cancer (PCa). MRI-guided micro-US FLA shows potential for outpatient use, but its clinical application remains unexplored. Purpose To evaluate the safety, feasibility, and 12-month functional and oncologic outcomes of MRI-guided micro-US transperineal FLA in localized PCa and to assess the accuracy of micro-US in showing lesions depicted at MRI with Prostate Imaging Reporting and Data System (PI-RADS) score of 3 or higher.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!